Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
147.07
+0.95 (0.65%)
Jun 22, 2026, 4:00 PM EDT - Market closed
Belite Bio Employees
Belite Bio had 41 employees as of December 31, 2025. The number of employees increased by 16 or 64.00% compared to the previous year.
Employees
41
Change (1Y)
16
Growth (1Y)
64.00%
Revenue / Employee
n/a
Profits / Employee
-$2,201,756
Market Cap
5.79B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 41 | 16 | 64.00% |
| Dec 31, 2024 | 25 | 5 | 25.00% |
| Dec 31, 2023 | 20 | 4 | 25.00% |
| Dec 31, 2022 | 16 | 4 | 33.33% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Caris Life Sciences | 1,846 |
| Travere Therapeutics | 497 |
| Mirum Pharmaceuticals | 418 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
BLTE News
- 8 days ago - Belite Bio completes rolling submission of NDA to U.S. FDA for tinlarebant - TheFly
- 10 days ago - Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - GlobeNewsWire
- 14 days ago - Belite Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 20 days ago - Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 27 days ago - Belite Bio Transcript: Stifel 2026 Virtual Ophthalmology Forum - Transcripts
- 27 days ago - Belite Bio price target lowered to $215 from $223 at Mizuho - TheFly
- 4 weeks ago - Belite Bio Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Belite Bio Earnings release: Q1 2026 - Filings